-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1513 Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Combination therapy, Diseases, Therapies, Myeloid Malignancies
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Domenico Russo, MD, PhD1*, Nicola Polverelli, MD1, Stella Santarone, MD2*, Francesco Onida, MD3*, Luca Castagna, MD4*, Stefania Bramanti5*, A. M. Carella, MD6,7*, Roberto Sorasio, MD8*, Attilio Olivieri9*, Germana Beltrami, MD10*, Antonio Curti, MD, PhD11, Calogero Vetro, MD12*, Valentina Mancini, MD13*, Elisabetta Terruzzi, MD14*, Massimo Bernardi, MD15*, Piero Galieni, MD16*, Pellegrino Musto, MD17*, Raffaella Cerretti, MD, PhD18*, Luisa Giaccone, MD, PhD19*, Cristina Skert20*, Erika Borlenghi, MD21*, Mirko Farina, MD1*, Alessandro Leoni1,22*, Vera Radici, MD1*, Simona Bernardi, PhD1,23*, Marika Vezzoli24*, Stefano Calza24*, Angela Gheorghiu25*, Michele Malagola1*, Massimo Martino, MD26* and Fabio Ciceri27*

1Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
2Centro Trapianti Midollo Osseo; Azienda Sanitaria Locale di Pescara, Pescara, ITA
3Hematology Unit - ASST Fatebenefratelli-Sacco - University of Milan, Milan, Italy
4Bone Marrow Transplantation Unit, Palermo, Italy, ITA
5Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy
6Azienda Ospedaliera San Martino, Genova, ITA
7Casa Sollievo Della Sofferenza, San Giovanni Rotondo (FG), Italy
8Department of Hematology, S. Croce e Carle Hospital, Cuneo, CN, ITA
9Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
10U.O. Ematologia e terapie cellulari, IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy
11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
12Division of hematology, A.O.U. Policlinico G.Rodolico – S. Marco, Catania, Italy
13Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
14Hematology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
15Unit of Hematology and Bone Marrow Transplantation, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy
16UOC Hematology, Mazzoni Hospital-Ascoli Piceno, Ascoli Piceno, Italy
17UOC Ematologia, Bari, Italy, ITA
18Department of Hematology, Stem Cell Transplant Unit, Policlinico Tor Vergata,, Rome, ITA
19Univesity of Torino, AOU Città Della Salute E Della Scienza Di Torino,, Torino, ITA
20Unit of Haematology/Bone Marrow Transplantation, Unit "ospedale Dell'Angelo", Venezia Mestra, ITA
21Hematology, ASST Spedali Civili, Brescia, Italy
22CREA Laboratory (Hematological-Research AIL Centre), ASST-Spedali Civili Brescia, Brescia, Italy
23Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, Brescia, Italy
24Biostatistics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
25Trials Office GITMO Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia Cellulare, Genova, Italy
26Centro Unico Trapianti A, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
27Unit of Hematology and Stem Cell Transplantation, Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy


Allogeneic stem cell transplantation (allo-SCT) is widely regarded as the most effective consolidation treatment for patients with intermediate to high-risk ELN AML. However, despite its potential curative benefits, many elderly patients (aged ≥60) are unable to undergo this procedure due to comorbidities and/or inability to tolerate intensive chemotherapy and achieve a complete remission (CR). As a result, only a small proportion of these patients are able to benefit from allo-SCT.


The VEN-DEC GITMO trial is a prospective, multicenter, single arm, phase II study designed to assess the safety and efficacy of a "chemo-free" combination of Venetoclax and Decitabine (VEN-DEC) as a bridge to allo-SCT in elderly patients (60-75y) with intermediate to high-risk ELN AML. The primary endpoint of the study was the percentage of patients who underwent transplant in first CR. The study aimed to enroll 100 patients, with a projected dropout rate of 12%. The study was considered successful if 14 or more patients underwent transplant in CR.


Venetoclax (up to 400mg oral daily) plus decitabine (20 mg/m2 for 5 days every 28 days) were administered for 2 cycles. Patients who achieved complete remission (CR), defined according to ELN criteria as CR/CRi/MLFS, were required to undergo allo-SCT within 2 months. Patients who did not respond (NR) or achieved partial remission (PR) after C2 could receive an additional 2 cycles of the therapy, in order to achieve a CR prior to transplant. Patients who did not respond or achieved only a PR were discontinued from the study and could be treated according to the policies of their respective Centers.


Overall, 100 patients were enrolled by 25 Italian GITMO transplant Centers as of December 2022. The data cut-off was on July 17th, 2023. Table 1 provides details on the cohort's characteristics. Notably, more than 50% of patients presented with myelodysplasia-related changes and/or therapy-related AML, and 47% of cases had an abnormal karyotype.

Seven patients (7%) were excluded due to screening failure. The remaining 93 patients started the 1st cycle of treatment, and 78 patients completed the 2nd cycle of VEN-DEC and were evaluable for treatment response.

Overall, 58 patients achieved complete remission (CR/CRi/MLFS) after 2 cycles (74%), while partial or non-response occurred in 20 cases. Four out of 20 (20%) PR/NR patients at C2 achieved CR after two additional cycles of therapy for a total of 62/93 (67%). Overall 51 and 26 patients received a third and/or a fourth cycle of treatment after achieving CR after cycle 2 while waiting for transplant, due to logistical issues. According to the study protocol, the 1st cycle should be administered inpatient in all patients. C2, C3, and C4 were given outpatient in 79%, 93%, and 85% of cases, respectively. The median time to response was 65 days (range, 49-175). Overall, 38 (41%) patients were discontinued before transplant (7 cases for complications while on CR). A total of 19/93 (20%) patients died before transplant.

At the data cut-off, 51/93 (55%) treated patients and 51/62 CRs (82%) had successfully undergone allo-SCT. Figure 1 illustrates the course of study treatment.

A total of 139 grade ≥2 adverse events were reported in 56 patients (60%). Seventy events out of 139 (50%) were considered at least possibly related to study intervention. The following hematological toxicities were observed: prolonged grade ≥2 neutropenia was recorded in 34 out of 139 cases (24%), while anemia and decreased platelet counts were recorded in 7 cases (5%) and 3 cases (2%), respectively. Febrile neutropenia and infections were observed in 22 (16%) and 31 (22%) cases, respectively.


The results of the VEN-DEC GITMO trial demonstrate that the chemo-free VEN-DEC induction/consolidation regimen was highly effective, achieving a high rate of complete remission (CR 67%). Additionally, the regimen improved the feasibility of allo-SCT, with 55% of treated patients and 82% of those who achieved CR undergoing allo-transplantation (primary endpoint). Starting from C2, the regimen was administered in an outpatient setting in 80-90% of cases, which allowed patients to maintain their fitness and bridge to transplant in CR. The regimen also had a low clinical toxicity profile, with only 7 patients achieving CR discontinuing therapy due to adverse events.


Monica Bonzi, Sr. Clinical Lead - IQVIA RDS, Italy.

Disclosures: Russo: Medac, Abbvie, MSD, Jazz Pharma, Gilead, Novartis: Membership on an entity's Board of Directors or advisory committees; MSD, Novartis, Gilead, BMS, Medac: Honoraria. Polverelli: GSK: Honoraria; BMS: Honoraria; Abbvie: Honoraria; Novartis: Honoraria. Curti: Novartis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Vetro: BMS: Honoraria; Jazz Pharmaceuticals: Honoraria; ABBVIE: Honoraria. Borlenghi: Amgen, Incyte: Other: travel grants; AbbVie, BMS: Consultancy. Malagola: Biotest, MSD: Consultancy, Honoraria. Ciceri: ExCellThera: Other: Scientific Advisory Board .

Previous Abstract | Next Abstract >>
*signifies non-member of ASH